Analyst firms · HSBC · BNTX
HSBC BNTX price target and rating history
BioNTech SE (BNTX) · Health Care
HSBC rates BioNTech SE (BNTX) Buy with a $111 price target, as of its latest action on Aug 2, 2024. It has published 3 rating actions on BNTX since July 2023, including 1 upgrade and 1 downgrade. Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.
- Current rating
- Buy
- Price target
- $111
- Median target, all firms
- $113
- Actions on BNTX
- 3
HSBC price target on BNTX
Every HSBC rating on BNTX
- Aug 2, 2024
- Oct 16, 2023
- Jul 14, 2023
How other firms rate BNTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Hold | Oct 8, 2026 | |
| BMO Capital Markets | Market Perform | $105 | Sep 8, 2026 |
| UBS | Buy | $135 | May 27, 2026 |
| Bernstein | Mkt Perform | $96 | May 22, 2026 |
| Leerink Partners | Market Perform | $113 | Feb 2, 2026 |
| Goldman Sachs | Buy | $142 | Jan 16, 2026 |
Questions about HSBC and BNTX
- What is HSBC's price target for BNTX?
- HSBC's latest stated price target for BioNTech SE (BNTX) is $111, from its action on Oct 16, 2023.
- What is HSBC's rating on BNTX?
- HSBC rates BNTX Buy, a bullish rating, as of Aug 2, 2024.
- When did HSBC last change its view on BNTX?
- On Aug 2, 2024, HSBC upgrades to Buy from Hold.
- How does HSBC's BNTX target compare with other analysts?
- Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.
More BNTX rating histories
All HSBC ratingsBNTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.